In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Previous research has shown that HIV-specific CD8 T-cell responses directed against five genetically conserved HIV-1 protein ...

Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.

Photo: belyaaa via 123rf New research employing mRNA technology — which gained prominence during the COVID-19 pandemic — may offer the key to developing a cure for HIV. One of the chief ...

There are several early-stage human clinical trials of HIV-vaccine components underway. Three mRNA- based early human trials of such components have been launched since 2022.

There are several early-stage human clinical trials of HIV-vaccine components underway. Three mRNA- based early human trials of such components have been launched since 2022.

Case in point: Covid. Thanks to HIV research, the mRNA vaccine technology was already available in 2020 to speed a coronavirus vaccine to market.